FASN and CD36 Predict Survival in Rituximab-treated Diffuse Large B-cell Lymphoma

Overview

Journal J Hematop

Publisher Springer

Specialty Hematology

Date 2015 May 5

PMID 25937841

Citations 10

Authors

Olga V Danilova

Larry J Dumont

Norman B Levy

Frederick Lansigan

William B Kinlaw

Alexey V Danilov

Prabhjot Kaur

Affiliations

Soon will be listed here.

Abstract

Diffuse large B-cell lymphoma is the most common lymphoid malignancy, as it accounts for approximately one third of all patient cases of non-Hodgkin's lymphoma. Patients with diffuse large B-cell lymphoma have markedly different treatment outcomes, suggesting a need for reliable prognostic factors and novel therapeutic approaches. De novo fatty acid synthesis is an important metabolic driver of tumor in multiple malignancies. In this retrospective study, we analyzed expression of fatty acid synthase (a key enzyme in de novo fatty acid synthesis), Spot 14 (thyroid hormone responsive Spot 14, a nuclear protein that promotes expression of genes involved in fatty acid synthesis), and CD36 (the cell surface channel for exogenous fatty acid uptake) in patients with diffuse large B-cell lymphoma and their clinical significance. We observed that overexpression of fatty acid synthase is negatively associated with overall survival (=0.001) and progression-free period (=0.004) in patients with diffuse large B-cell lymphoma. Multivariate analysis showed that fatty acid synthase overexpression is an independent prognostic marker of aggressive clinical course. For the first time, we report CD36 as an independent protective factor in patients treated with rituximab. Thus, fatty acid synthase and CD36 expression may serve as prognostic markers to predict response to treatment and survival in diffuse large B-cell lymphoma patients. Fatty acid synthase may also be a potential therapeutic target in lymphoid malignancies.

Citing Articles

Tumor Biology Hides Novel Therapeutic Approaches to Diffuse Large B-Cell Lymphoma: A Narrative Review.

Masnikosa R, Cvetkovic Z, Piric D Int J Mol Sci. 2024; 25(21).

PMID: 39518937 PMC: 11545713. DOI: 10.3390/ijms252111384.

Baseline tumor gene expression signatures correlate with chemoimmunotherapy treatment responsiveness in canine B cell lymphoma.

Dittrich K, Yildiz-Altay U, Qutab F, Kwong D, Rao Z, Nievez-Lozano S PLoS One. 2023; 18(8):e0290428.

PMID: 37624862 PMC: 10456153. DOI: 10.1371/journal.pone.0290428.

Disturbed Plasma Lipidomic Profiles in Females with Diffuse Large B-Cell Lymphoma: A Pilot Study.

Masnikosa R, Piric D, Post J, Cvetkovic Z, Petrovic S, Paunovic M Cancers (Basel). 2023; 15(14).

PMID: 37509314 PMC: 10377844. DOI: 10.3390/cancers15143653.

Orchestral role of lipid metabolic reprogramming in T-cell malignancy.

Mehta A, Ratre Y, Soni V, Shukla D, Sonkar S, Kumar A Front Oncol. 2023; 13:1122789.

PMID: 37256177 PMC: 10226149. DOI: 10.3389/fonc.2023.1122789.

Reprogramming lipid metabolism as potential strategy for hematological malignancy therapy.

Zhang L, Chang N, Liu J, Liu Z, Wu Y, Sui L Front Oncol. 2022; 12:987499.

PMID: 36106108 PMC: 9465383. DOI: 10.3389/fonc.2022.987499.

References

Alo P, Visca P, Trombetta G, Mangoni A, Lenti L, Monaco S . Fatty acid synthase (FAS) predictive strength in poorly differentiated early breast carcinomas. Tumori. 1999; 85(1):35-40. DOI: 10.1177/030089169908500108. View

Hans C, Weisenburger D, Greiner T, Gascoyne R, Delabie J, Ott G . Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2003; 103(1):275-82. DOI: 10.1182/blood-2003-05-1545. View

Warburg O . On the origin of cancer cells. Science. 1956; 123(3191):309-14. DOI: 10.1126/science.123.3191.309. View

Kinlaw W, Quinn J, Wells W, Roser-Jones C, Moncur J . Spot 14: A marker of aggressive breast cancer and a potential therapeutic target. Endocrinology. 2006; 147(9):4048-55. DOI: 10.1210/en.2006-0463. View

KINLAW W, Church J, Harmon J, Mariash C . Direct evidence for a role of the "spot 14" protein in the regulation of lipid synthesis. J Biol Chem. 1995; 270(28):16615-8. DOI: 10.1074/jbc.270.28.16615. View

Gatenby R, Gillies R . Why do cancers have high aerobic glycolysis?. Nat Rev Cancer. 2004; 4(11):891-9. DOI: 10.1038/nrc1478. View

Kuhajda F . Fatty acid synthase and cancer: new application of an old pathway. Cancer Res. 2006; 66(12):5977-80. DOI: 10.1158/0008-5472.CAN-05-4673. View

Jump D, OPPENHEIMER J . High basal expression and 3,5,3'-triiodothyronine regulation of messenger ribonucleic acid S14 in lipogenic tissues. Endocrinology. 1985; 117(6):2259-66. DOI: 10.1210/endo-117-6-2259. View

Alo P, Visca P, Marci A, Mangoni A, Botti C, Di Tondo U . Expression of fatty acid synthase (FAS) as a predictor of recurrence in stage I breast carcinoma patients. Cancer. 1996; 77(3):474-82. DOI: 10.1002/(SICI)1097-0142(19960201)77:3<474::AID-CNCR8>3.0.CO;2-K. View

10.

Uddin S, Hussain A, Ahmed M, Bu R, Ahmed S, Ajarim D . Inhibition of fatty acid synthase suppresses c-Met receptor kinase and induces apoptosis in diffuse large B-cell lymphoma. Mol Cancer Ther. 2010; 9(5):1244-55. DOI: 10.1158/1535-7163.MCT-09-1061. View

11.

WEISS L, Hoffmann G, Schreiber R, Andres H, Fuchs E, KORBER E . Fatty-acid biosynthesis in man, a pathway of minor importance. Purification, optimal assay conditions, and organ distribution of fatty-acid synthase. Biol Chem Hoppe Seyler. 1986; 367(9):905-12. DOI: 10.1515/bchm3.1986.367.2.905. View

12.

Kennedy D, Kashyap S . Pathogenic role of scavenger receptor CD36 in the metabolic syndrome and diabetes. Metab Syndr Relat Disord. 2011; 9(4):239-45. DOI: 10.1089/met.2011.0003. View

13.

Kuhajda F, Pizer E, Li J, Mani N, Frehywot G, Townsend C . Synthesis and antitumor activity of an inhibitor of fatty acid synthase. Proc Natl Acad Sci U S A. 2000; 97(7):3450-4. PMC: 16260. DOI: 10.1073/pnas.97.7.3450. View

14.

Koch M, Hussein F, Woeste A, Grundker C, Frontzek K, Emons G . CD36-mediated activation of endothelial cell apoptosis by an N-terminal recombinant fragment of thrombospondin-2 inhibits breast cancer growth and metastasis in vivo. Breast Cancer Res Treat. 2010; 128(2):337-46. PMC: 3291836. DOI: 10.1007/s10549-010-1085-7. View

15.

Milgraum L, Witters L, Pasternack G, Kuhajda F . Enzymes of the fatty acid synthesis pathway are highly expressed in in situ breast carcinoma. Clin Cancer Res. 1998; 3(11):2115-20. View

16.

Rutella S, Rumi C, Puggioni P, Barberi T, Di Mario A, Larocca L . Expression of thrombospondin receptor (CD36) in B-cell chronic lymphocytic leukemia as an indicator of tumor cell dissemination. Haematologica. 1999; 84(5):419-24. View

17.

Westin J, Fayad L . Beyond R-CHOP and the IPI in large-cell lymphoma: molecular markers as an opportunity for stratification. Curr Hematol Malig Rep. 2010; 4(4):218-24. DOI: 10.1007/s11899-009-0029-y. View

18.

Donnelly C, Olsen A, Lewis L, Eisenberg B, Eastman A, Kinlaw W . Conjugated linoleic acid (CLA) inhibits expression of the Spot 14 (THRSP) and fatty acid synthase genes and impairs the growth of human breast cancer and liposarcoma cells. Nutr Cancer. 2009; 61(1):114-22. PMC: 2872989. DOI: 10.1080/01635580802348666. View

19.

Rahman L, Voeller D, Rahman M, Lipkowitz S, Allegra C, Barrett J . Thymidylate synthase as an oncogene: a novel role for an essential DNA synthesis enzyme. Cancer Cell. 2004; 5(4):341-51. DOI: 10.1016/s1535-6108(04)00080-7. View

20.

Sehn L, Donaldson J, Chhanabhai M, Fitzgerald C, Gill K, Klasa R . Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol. 2005; 23(22):5027-33. DOI: 10.1200/JCO.2005.09.137. View